Holliston

Biostage, a cell-therapy biotech company based in Holliston, has received $6 million in commitments from investors to accelerate its clinical development program.

The directory is a list of organizations with a location in Central Massachusetts that support the life sciences industry, including contract research organizations, contract development and manufacturing organizations, and companies providing custom products, technologies, or other services.

Holliston biotechnology company Biostage, Inc. has selected Jerry He as its new leader, naming him as CEO and chairman of its board to replace company founder David Green.

Oligo Factory, a Holliston-based biomanufacturer, opened Thursday a new 13,000 square foot facility to scale-up its production processes. The new facility will serve as Oligo’s new headquarters and will increase manufacturing capabilities for the company by a factor of 12.

Biostage, Inc. in Holliston has removed the interim designation from David Green’s title and made him biotechnology company’s CEO.

Harvard Bioscience, Inc. named Jennifer Cote as the company’s chief financial officer and treasurer following the resignation of Michael Rossi, according to a Monday press release from the company.

MassDevelopment made 18 grants totalling more than $1.5 million to businesses, cities, towns, and nonprofit organizations in Central Mass.

Holliston bioscience company Biostage has hired a public financing and Nasdaq listing expert as its new CFO. 

Holliston biotechnology company Biostage Inc. has secured a patent to allow the company known for its esophageal cancer treatment research to pursue treatments for lung cancer.

MassDevelopment, the state’s development agency, issued a $16.5-million tax-exempt bond to Attleboro autism services nonprofit Amego Inc., to buy 16 facilities, including seven in Central Massachusetts.